Kymera Therapeutics

Kymera Therapeutics to Participate in Upcoming September Conferences

WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Founder, President and